#sustained virologic response

Once you’ve officially rid yourself of hepatitis C, how certain can you be that the virus is gone for good?

Treatment for hep C is easier than ever before. In clinical trials, roughly 95 percent of those who took the newest meds were cured.

Ridding the body of hep C reduces central fatigue, which is weakness originating in the central nervous system.

Sofosbuvir and ribavirin cured between 67 and 88 percent of those coinfected with HIV and genotypes 1, 2 or 3 of hepatitis C virus in a recent...

Preliminary data from a trial of daclatasvir, asunaprevir and BMS-791325 showed hepatitis C cure rates around 90 percent.

Victrelis, when added to interferon and ribavirin, improves cure rates of hepatitis C and does not raise major treatment risks in those coinfe...

Much attention is focused on the effort to achieve a cure for hepatitis C. But what actually happens after the virus is finally gone?

People with cirrhosis who are cured of hepatitis C have significantly lowered risk of liver decompensation, liver cancer and death.

Adding Incivek to pegylated interferon and ribavirin doubles the cure rate and cuts in half the treatment time for acute hepatitis C among HIV...

Promising Phase III results from a trial of Gilead Sciences’s hepatitis C antiviral sofosbuvir open the door for regulatory filing this...

With numerous obstacles preventing widespread treatment of the U.S. hepatitis C population, how can the health care system successfully...

For people with hepatitis C and chronic liver disease, retreatment with interferon monotherapy is unlikely to improve their condition and may...

Gilead Sciences has announced promising data on its hepatitis C triple therapy, sofosbuvir, GS-5885, and ribavirin, which is headed toward..

Promising results in studies are tempered by myriad barriers against successfully treating and curing the disease in real world settings.

The hepatitis C pipeline: huge changes on the horizon

Investigational agents daclatasvir and asunaprevir have shown high cure rates among prior null-responders with difficult-to-treat strains of h...